Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling Study in patients with type 2 diabetes

Reimer, Tanja; Hohberg, C.; Pfützner, A.; Jørgensen, Christina Mørup; Jensen, Klaus H.; Pfützner, Andreas

doi:10.1016/j.clinthera.2008.12.004

Cited by 25 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the sample size was large (much greater than that used in other similarly designed studies 16,17 ), and the results were reproducible in each of the five countries involved. It is important to note that none of the participants had prior experience of using the ClikSTAR pen.…”

Section: Insulin Pen User Studymentioning

confidence: 86%

Performance of a New Reusable Insulin Pen

Penfornis

2011

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Background: The aim of this multinational (Canada, France, Germany, United Kingdom, and United States), task and interview-based study was to compare the ease of use and performance of the ClikSTAR Ò (sanofi-aventis, Paris, France) insulin pen with other commonly used reusable pens based on participant and interviewer assessments. Methods: People with diabetes (n ¼ 654) were asked to demonstrate four pens consecutively-ClikSTAR, Lilly Luxura Ò (Eli Lilly, Indianapolis, IN), and NovoPen Ò 3 and 4 (Novo Nordisk, Bagsvaerd, Denmark)-according to the respective instruction manuals. The endpoint was assessed by a rating from the participants and the interviewer. While the participants focused on the pen's ease of use, the interviewer considered the participants' difficulty in preparing and delivering a 40-unit dose and their requirement for help. Results: Twenty percent of U.S. participants and 24% of participants from the other countries had type 1 diabetes. Approximately 50% of participants in each group had prior insulin pen experience. A higher proportion of participants, including those with dexterity or visual impairments, reported ClikSTAR as easier to use than other pens (P < 0.05). Participants using ClikSTAR did not experience any difficulty in completing the tasks. The proportion of participants not requiring help in completing the tasks with ClikSTAR was rated as numerically higher than, or similar to, that observed with Lilly Luxura or NovoPen 3 or 4 (75%, 74%, 62%, and 65%, respectively). According to participants, ClikSTAR and NovoPen 4 emerged as the most highly rated pens. Conclusions: In comparison with other pens, ClikSTAR was significantly easier to use, which, when taken together with overall performance, meets the need of people with diabetes.

show abstract

Section: Insulin Pen User Studymentioning

confidence: 86%

Performance of a New Reusable Insulin Pen

Penfornis

2011

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…[23][24][25][26][27][28] A key aspect of any pen device is that it should require minimal training on device initiation and maintained use, as the procedure should be easy to teach and to learn. 29,30 The PDS290 pen injector (FlexTouch ® ) is a novel device designed to address specific usability issues and to be used safely and effectively for all intended users, uses and use environments. FlexTouch ® is currently approved in combination with insulin detemir/insulin aspart in the United States and several other combinations in Europe.…”

mentioning

confidence: 99%

Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience

Fujioka

Sparre

Sun

et al. 2015

J Diabetes Sci Technol

View full text Add to dashboard Cite

Obesity is a chronic disease often encompassed by a multitude of serious comorbidities, making its prevention and treatment public health priorities. Globally, by 2030, the numbers of adults who are overweight ( It has been shown that an increase in BMI is directly correlated with a reduction in life expectancy and increase in obesity-related comorbidities such as type 2 diabetes mellitus (T2DM).3-5 A 5-10% weight loss can provide clinically relevant improvements in obesity-related comorbidities and quality of life (QoL).6,7 Depending on BMI classification and the number/severity of comorbidities, behavioral therapy including dietary and physical activity changes, pharmacotherapy and (in the appropriate patient) bariatric surgery are recommended. 8,9 However, achieving and maintaining weight loss by diet and physical activity alone can be challenging.10-12 Pharmacotherapy supports weight loss and Background: Obesity is associated with multiple comorbidities and increased mortality, making it an important target for treatment. However, achieving and maintaining weight loss by diet and physical activity remains challenging, and may often require pharmacotherapy. Liraglutide 3.0 mg has recently been approved for weight management in the United States, Canada, and EU. The current analysis used a summative usability test to assess safety and effectiveness, ease of use, and training requirements for the novel liraglutide 3.0 mg pen injector.

show abstract

“…In general, differences in the injection force among insulin pens are relatively small; however, the improved FlexPen does seem to show benefits when compared with SoloSTAR and OptiClik pens. 70 A separate study also showed a 71 Results of other studies have shown an overall preference for SoloSTAR (53%) rather than for the original FlexPen (31%) or Humulin/Humalog pen (15%), 72 with the SoloSTAR and original FlexPen found to be more user-friendly than the Eli Lilly disposable pen. 73 To date, there are no studies comparing patient preference for the improved FlexPen compared with the SoloSTAR or Humulin/Humalog Pen.…”

Section: Clinical Studies Comparing Insulin Pensmentioning

confidence: 90%

Practical Aspects of Insulin Pen Devices

Pearson

2010

J Diabetes Sci Technol

View full text Add to dashboard Cite

Insulin pen devices have several advantages over the traditional vial-and-syringe method of insulin delivery, including improved patient satisfaction and adherence, greater ease of use, superior accuracy for delivering small doses of insulin, greater social acceptability, and less reported injection pain. In recent years, pens have become increasingly user-friendly, and some models are highly intuitive to use, requiring little or no instruction. Despite this progress, uptake of these devices in the United States has not matched that in many other areas of the world. There is a need for improved awareness of the current characteristics of insulin pen devices among United States health care professionals. Knowledge of the design improvements that have been incorporated into pens, both to address patient needs and as a result of the improved technology behind the device mechanics, is essential to promoting the use of insulin pen devices. This review highlights some of the practical aspects of pen use and discusses the factors to be considered when selecting among different insulin pens.

show abstract

Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling Study in patients with type 2 diabetes

Cited by 25 publications

References 11 publications

Performance of a New Reusable Insulin Pen

Performance of a New Reusable Insulin Pen

Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience

Practical Aspects of Insulin Pen Devices

Contact Info

Product

Resources

About